Aptahem plans for a rights issue of SEK 9.7 million
Swedish biotech company Aptahem has announced a rights issue of approximately SEK 9.7 million aimed at financing the continued clinical development of its lead drug candidate, Apta-1. The therapeutic candidate is being developed for the treatment of life-threatening inflammatory conditions, including sepsis.
The board of directors of Aptahem has resolved on the rights issue, subject to approval by an extraordinary general meeting scheduled for May 13, 2025. The company intends to offer existing shareholders the opportunity to participate under preferential terms.
The subscription price in the rights issue amounts to SEK 1.0 per share, to be compared with a share price of SEK 1.36 by closing yesterday. As per usual, the market reacted negatively to the news and plummeted over 30 per cent this morning. At the time of writing the share price has stabilised at around SEK 1.10 and is thus traded above the suggested subscription price.
The net proceeds of maximum SEK 9.7 million are expected to fund the continued business development in preparation for a potential future partnership, to complete a regulatory-approved study package enabling a phase II clinical trial in collaboration with a partner. The capital will also be used to strengthen Aptahem’s working capital and liquidity.
Strategic focus and financing needs
Aptahem is actively progressing its pipeline in RNA-based drug development, with Apta-1 as the primary candidate. The funds raised through the offering are intended to support further regulatory and clinical work required to advance the program. This includes process development, documentation, and planning associated with the company’s phase II strategy.
The financing initiative aligns with Aptahem’s broader objective to accelerate the development of novel therapeutics for severe systemic inflammation and coagulation disorders. The company has previously reported promising early clinical data for Apta-1, confirming solid safety and tolerability, supporting its continued investment in the project.
Looking ahead
With the proposed capital raise, Aptahem aims to ensure operational continuity and maintain the pace of development within its lead program. The rights issue is expected to strengthen the company’s position ahead of the next key clinical milestones.
Additional information, including detailed terms and the prospectus, will be made available through the company’s official channels following the extraordinary general meeting.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
